UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.27-36.e1

2015

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Volltextzugriff (PDF)

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Volltextzugriff (PDF)

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Journal of the American Academy of Dermatology, 2012-08, Vol.67 (2), p.245-256

2012

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Volltextzugriff (PDF)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Volltextzugriff (PDF)

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA dermatology (Chicago, Ill.), 2015-09, Vol.151 (9), p.961

2015

Volltextzugriff (PDF)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Volltextzugriff (PDF)

Etanercept as Monotherapy in Patients with Psoriasis

The New England journal of medicine, 2003-11, Vol.349 (21), p.2014-2022

2003

Volltextzugriff (PDF)

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Journal of the American Academy of Dermatology, 2005-03, Vol.52 (3), p.425-433

2005

Volltextzugriff (PDF)

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Journal of drugs in dermatology, 2016-05, Vol.15 (5), p.562

2016

Volltextzugriff (PDF)

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Journal of drugs in dermatology, 2013-08, Vol.12 (8), p.888

2013

Volltextzugriff (PDF)

Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

Journal of the American Academy of Dermatology, 2006-03, Vol.54 (3), p.S92-S100

2006

Volltextzugriff (PDF)

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2006-04, Vol.54 (4), p.S164-S170

2006

Volltextzugriff (PDF)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

The Lancet (British edition), 2013-08, Vol.382 (9894), p.780-789

2013

Volltextzugriff (PDF)

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Volltextzugriff (PDF)

Concurrent herpes simplex and varicella-zoster infection in an immunocompromised patient

Journal of the American Academy of Dermatology, 1995-07, Vol.33 (1), p.126-129

1995

Volltextzugriff (PDF)

Role of Mycobacterium paratuberculosis in Crohn's disease : A prospective, controlled study using polymerase chain reaction

Diseases of the colon & rectum, 1998-02, Vol.41 (2), p.195-199

1998

Volltextzugriff (PDF)

Identification of Mycobacterium tuberculosis DNA in a case of lupus vulgaris

Journal of the American Academy of Dermatology, 1993-02, Vol.28 (2), p.318-322

1993

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(35)
Male
(33)
Science & Technology
(33)
Female
(32)
Life Sciences & Biomedicine
(32)
Adult
(29)
Dermatology
(26)
Psoriasis - Drug Therapy
(25)
Biological And Medical Sciences
(18)
Double-Blind Method
(18)
Medical Sciences
(18)
Severity Of Illness Index
(18)
Aged
(17)
Psoriasis
(17)
Treatment Outcome
(15)
Antibodies, Monoclonal - Adverse Effects
(11)
Antibodies, Monoclonal - Therapeutic Use
(11)
General & Internal Medicine
(10)
Medicine, General & Internal
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Etanercept as Monotherapy in Patients with Psoriasis

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Concurrent herpes simplex and varicella-zoster infection in an immunocompromised patient

Role of Mycobacterium paratuberculosis in Crohn's disease : A prospective, controlled study using polymerase chain reaction

Identification of Mycobacterium tuberculosis DNA in a case of lupus vulgaris

Aktive Filter

Suchergebnisse filtern